CTL019 approval likely in pALL, ad-com positive
With a probable approval for Novartis’s CTL019 (tisagenlecleucel) (OXB manufacture a key component) in both paediatric ALL and DLBCL on the...
107 Views
Lentiviral vector supply for CTL019 driving revenue growth
Oxford BioMedica has today announced a significant agreement with Novartis for the ongoing commercial and clinical supply of lentiviral vectors...
83 Views
CTL019 and product out-licensing to drive 2017
We expect Oxford BioMedica’s (OXB’s) strategic vision to come to further fruition through 2017/18 with both the potential approval of Novartis’s...
136 Views
Encouraging CTL019 data in paediatric r/r B-ALL
At ASH this weekend, Novartis presented data from its global registration trial (ELIANA) of CTL019 in relapsed/refractory (r/r) paediatric and...
91 Views
Orchard deal adds to growing revenue stream
Oxford BioMedica’s (OXB’s) recently announced strategic alliance with Orchard Therapeutics further underpins the value the wider cell therapy...
93 Views